In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Vectura to buy SkyePharma for $621mm

Executive Summary

Vectura Group PLC agreed to buy SkyePharma PLC for consideration of $621mm (£441mm). SkyePharma shareholders will receive 2.7977 new shares for each share held (£441.3mm valuation; 410.15p per share representing 7% premium over prior 10-day trading average). Alternatively shareholders can choose to receive partial consideration in cash. Annual pre-tax synergies are expected to be around £10mm, and will be fully realized by 2018.

Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
      • Topical Delivery
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies